Exceptional PARP inhibitor responders: the good and the bad

Editor’s Choice: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaEditorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome dataHosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorialFeaturing: David O'Malley, MD, The Ohio State UniversityCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net